The Next Step in Killing Cancer
Source: Martin Biancuzzo, The Daily Reckoning  (9/16/13)
"After several years of trial and error, Olson and his team at the privately owned Seattle biotech firm Blaze Bioscience, have created something called 'tumor paint.' And the solution has come from the most unlikely of places. . .Scorpion venom." More >

Hidden Finds in Regenerative and Medical Technology: Jeff Cohen
Source: Peter Byrne of The Life Sciences Report  (9/12/13)
Ladenburg Thalmann & Co. Inc.'s Jeff Cohen regularly explores the frontiers of regenerative and medical technology looking for solid investment opportunities. In this interview with The Life Sciences Report, Cohen reveals promising finds in one of the world's fastest-growing business sectors. From robotics to skin grafts, Cohen knows his science and his market. More >

Griffin Securities' Keith Markey Gives Performance Reviews on Four Favorite Biotech Names
Source: Peter Byrne of The Life Sciences Report  (9/12/13)
As science director for Griffin Securities, Keith Markey knows his way around the advanced technologies of the most promising research in biotech. In this interview with The Life Sciences Report, Markey explains the science behind new developments in the antibiotic, diabetic and dermatological fields, highlighting ground-floor investment opportunities that investors will not want to miss. More >

Medtech Stock Update: Public Policy Forces Restructuring, M&A Activity
Source: Zacks Equity Research  (9/10/13)
"The Patient Protection and Affordable Care Act (PPACA), particularly the medical device excise tax, has taken a heavy toll on the medtech sector, hurting pricing decisions of the companies and subjecting them to tremendous margin pressure." More >

Digging Below the Surface of Neurotechnology: Casey Lynch
Source: George S. Mack of The Life Sciences Report  (9/5/13)
Neuroscience is about as complex as it gets. The central nervous system contains the brain and spinal cord, where hundreds of billions of neurons are located—and that doesn't include the peripheral nervous system. Casey Lynch, managing director of NeuroInsights, works to make sense of both the disease processes affecting the nervous system and potential therapies that could help patients and enrich investors. In this interview with The Life Sciences Report, Lynch brings some clarity to the complexity, and speaks frankly about the wild goose that some Alzheimer's disease investigators have been chasing. More >

Medical Conference Schedule Sept. 2013 through March 2014
Source: Michael King, JP Morgan  (9/5/13)
More >

Scientific Conferences Create Buzz and Move Biotech Stocks: Michael King
Source: George S. Mack of The Life Sciences Report  (9/5/13)
It's that time again. From Labor Day through the New Year, analysts jet off to conferences across the U.S. and Europe to hear data they've been waiting on for years. Michael King, managing director and senior biotechnology analyst at JMP Securities, has been at this game for almost two decades, and he has a firm grip on how data releases about molecules and their targets will affect the biotech stocks in his coverage. In this interview with The Life Sciences Report, King also names four growth companies making important advances in hematologic cancers. Just in time. More >

Breakthrough Therapy Designation Speeds Up Drug Approvals
Source: Patricia Dimond, Genetic Engineering and Biotechnology News  (9/4/13)
"The FDA's new development path is specifically designed for experimental agents that produce large and unprecedented treatment effects in early clinical trials. If a drug is designated a breakthrough therapy, the FDA says it will expedite the development and review of the drug." More >

Biotech Investor Realism with Andrew Fein
Source: Peter Byrne of The Life Sciences Report  (8/29/13)
Expert healthcare company watcher Andrew Fein of H.C. Wainwright & Co. knows how the sausage is made in the stock analyst factory. And he doesn't pull any punches: In this interview with The Life Sciences Report, Fein dishes out praise for sticking to sellside fundamentals and suggests skimming off bloggers who have yet to earn their analytical chops. He rounds out the menu by naming biotech companies with the potential to rise to the top of the simmering biotech market. More >

Amgen Deal Highlights a Red-Hot Cancer Therapy Industry
Source: Tara Clarke, Money Morning  (8/26/13)
"Cancer therapy is a multibillion-dollar industry that will be the biggest M&A driver—and profit producer—for biotech investors." More >

Three New Picks from the Hot Biotech IPO Market: Ran Nussbaum
Source: George S. Mack of The Life Sciences Report  (8/22/13)
Ran Nussbaum, co-founder and managing partner of The Pontifax Group, is a venture capitalist seeking game-changing products that will create real value for patients, pharmas and investors. In this interview with The Life Sciences Report, Nussbaum addresses three public companies in different stages of development—from a penny stock with a preclinical value driver to a revenue-generating "larger" small-cap company developing novel products for critical orphan indications. As a bonus, Nussbaum drops two European biotech names that he believes are suffering from anonymity in U.S. markets. More >

Spot Tenbagger Discovery Potential in Biotech: Michael Berry
Source: George S. Mack of The Life Sciences Report  (8/22/13)
How do the best investors detect life science companies with the potential to generate significant wealth? Michael Berry, publisher of Morning Notes, found that traditional growth and value models didn't measure up, so he developed his own "discovery" strategy. He looks at companies that haven't gone public yet. He's not afraid of the penny stock. Find out more about Berry's technique, and about five companies that fit his profit-generating profile, in this interview with The Life Sciences Report. More >

Quest to Cure Cancer Spurs Big Gains in the Biotech Bull
Source: Ray Blanco, The Daily Reckoning  (8/20/13)
"There are still plenty of skeptics regarding the promise of this technology, but I'm not one of them. In fact, I believe biotechnology investors who don't participate in this new wave of cancer therapy will be missing out on historic profit opportunities." More >

Adventures in the Biotech Trade with Jim Letourneau
Source: Peter Byrne of The Life Sciences Report  (8/15/13)
Jim Letourneau, publisher of Big Picture Speculator, shares tales of strange biotechnologies worth buying into—such as cures for high dental bills and dog breath—in this interview with The Life Sciences Report. Letourneau likes to invest in biotech firms because their stock values are less volatile than commodity-based companies, which are chained to uncontrollable price fluctuations. You are advised to hold onto your brain (quite literally), while Letourneau describes a few curious—and potentially profitable—biotech investment adventures. More >

Still Time to Catch Big Growth in Biotech: George Zavoico
Source: George S. Mack of The Life Sciences Report  (8/15/13)
Biotech has had a scorching run for more than a year and a half, but as broader markets approach more realistic valuations with less potential upside, it becomes even more important to be invested in the right companies with truly meaningful catalysts on the horizon. George Zavoico of MLV & Co. knows how to pick winners from the field, and offers up solid ideas with visible growth drivers in this interview with The Life Sciences Report. Your inner gambler should take note: A beaten-down micro- or small-cap company might, with a bit of luck, bring home the gold. More >

The Best New Companies in a White-Hot Biotech Sector
Source: Michael Robinson, Money Morning  (8/9/13)
"IPO action is proof of the big bucks coming into biotech, igniting a strong rally in the entire sector for the rest of the year. So far this year, we've seen the most biotech IPOs in 13 years." More >

Wedbush Expert Declares Money for Biotech Is Still Out There
Source: George S. Mack of The Life Sciences Report  (8/8/13)
The bull market in biotech stocks is coming up on its two-year anniversary, and large-cap and many small-cap names have flourished in that time. But can it last? Greg Wade, managing director of Wedbush Securities, wants investors to know there's more to go, and that stocks are ready and willing to respond to good news from clinical trials and on the regulatory front. In this interview with The Life Sciences Report, Wade identifies six names that investors can take to the bank, one of which is still his favorite after two years. More >

Eight Small-Cap Medtechs with Big Prospects: Brian Marckx
Source: George S. Mack of The Life Sciences Report  (8/7/13)
Small-cap medical technology has long been regarded as the ugly duckling of biotech. . .but think again. Brian Marckx of Zacks Small-Cap Research believes that the real gems of the medtech space complement—and can even outshine—sexier drug and surgical therapies. In this interview with The Life Sciences Report, Marckx makes a strong case for eight small- and micro-cap names that could bring home huge returns for investors. More >

Our Worry-Free Way of Investing in Biotech
Source: Greg Madison, Money Morning  (8/2/13)
"We are on the cusp of some truly amazing discoveries. There is a tier of biotech companies working around the clock on products with amazing potential." More >

Off to the Races with Seven Extraordinary Biotech and Medtech Companies: Jason Napodano
Source: George S. Mack of The Life Sciences Report  (8/1/13)
Senior Biotechnology Analyst Jason Napodano of Zacks Investment Research specializes in uncovering small biotech and medtech companies with good prospects for successful drug development. He relishes proven management capable of creative financing to move private equity into the public markets, and he does not shy away from tiny companies outside the U.S. that have extraordinary technology. In this wide-ranging interview with The Life Sciences Report, Napodano presents the elegant growth stories of seven small companies that could return magnificent gains to investors. More >

Six Oncology-Focused Biotech Growth Engines: Mara Goldstein
Source: George S. Mack of The Life Sciences Report  (8/1/13)
For Cantor Fitzgerald Senior Biotechnology Analyst Mara Goldstein, the spotlight is always on oncology and the premium revenues commanded by new products in the space. That clarity brings the science, unmet needs and market opportunity into sharp focus for investors. In this interview with The Life Sciences Report, Goldstein makes a winning case for six cancer-focused companies that range from micro caps to genuine large-cap stocks, each with upside potential that could be stunning. More >

Meet High Risk and High Reward, Biotech's Profit Partners: Bert Hazlett
Source: George S. Mack of The Life Sciences Report  (7/25/13)
Small-cap biotech investing carries real risk. Startup companies tend to have only a few ideas in development, which leaves ample room for setbacks—even room for disaster. Robert "Bert" Hazlett, senior biotechnology research analyst with ROTH Capital Partners, doesn't mind taking such risks, but tempers them with a diversification strategy designed to minimize the impact of potential hiccups and blowups. In this interview with The Life Sciences Report,
Hazlett expands on his strategy and mentions four companies with experienced management teams and high hopes for huge returns.
More >

Mesoblast Ltd. Targets Success in the Degenerative Disc Space
Source: George S. Mack of The Life Sciences Report  (7/25/13)
The biggest challenge in the treatment of degenerative disc disease lies in the inhospitable nature of the intervertebral space, where the blood flow and nutrients necessary to cell survival are in short supply. Mesoblast Ltd. has developed a cell therapy that addresses that challenge, triggering the regenerative qualities of surrounding cells to promote healing. In this interview with The Life Sciences Report, Mesoblast Founder, CEO and Managing Director Silviu Itescu describes the science that promises relief to millions of back pain sufferers. More >

BioRestorative Therapies Inc. Develops Plug-and-Play Therapy for Bulging/Herniated Disc Disease
Source: George S. Mack of The Life Sciences Report  (7/25/13)

Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc., describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.

Is Cell Therapy the 'Future of Medicine'?: Jason Kolbert
Source: George S. Mack of The Life Sciences Report  (7/25/13)
The pricey evolutionary tradeoff for walking on two legs is the curse of lower back pain. Jason Kolbert of the Maxim Group understands the power of stem cells as disease-modifying therapies for degenerative disc disease of the spine, a leading-edge, multibillion-dollar indication. Kolbert explores the opportunities that cell therapies offer investors in this interview with The Life Sciences Report, and puts a personal spin on their regenerative promise. More >